By securing this patent, Laxxon Medical has considerably strengthened its intellectual property position within the pharmaceutical market!
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent 11,419,824 B2 to Laxxon Medical Corp. for the controlled administration of one or more active pharmaceutical ingredients within a drug delivery system via oral dosage forms.
U.S. Patent 11,419,824 B2 covers the controlled administration of one or more active pharmaceutical ingredients (APIs) within a drug delivery system (DDS) via an oral dosage form.
“Multi-drug medications and 3D printing are fierce emerging players in the pharmaceutical industry. These new technologies are pushing the boundaries of medicine and defining the next generation of healthcare,” said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical.
“This patent represents a major milestone in Laxxon’s development strategy and establishes Laxxon as a leader in the 3D printed pharmaceuticals market.”
The addition of this patent considerably strengthens Laxxon Medical’s position, adding to its patent portfolio, which currently boasts over 150 patents, licenses, and patent applications in addition to over 3,000 patent claims.
About Laxxon’s Drug Delivery System (DDS)
Laxxon Medical’s drug delivery system is a 3D screen-printed oral, intra, or transdermal dosage, which, due to the exact arrangement of the active pharmaceutical ingredient (API) within the system, will allow for customized administration and release profiles of one or more therapeutic applications within the patient.
Laxxon Medical is disrupting the current pharmaceutical drug delivery and manufacturing landscape through our innovative, patented SPID®-Technology (Screen Printing Innovational Drug Technology).
The drug delivery system fully optimizes pharmacokinetics and pharmacodynamics, yielding optimal clinical results and fewer side effects, all while requiring less API than conventional DDS methods. In addition, Laxxon Medical’s drug delivery system is not limited to a particular API, which allows for mass application among pharmaceutical drug therapies.
Laxxon Medical is committed to engineering patented 3D pharmaceutical solutions that will optimize the effectiveness of medications and ultimately benefit the patients they’re intended for.
Laxxon strives to accelerate pharmaceutical progress globally by establishing itself as the leader in the field of 3D-printed drugs.
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions that optimize products and benefit patients. Our goal is to establish SPID®-Technology as a manufacturing process with the individual and the pharmaceutical partner in mind.
To keep up to date with SPID®-Technology and Laxxon Medical news and announcements, follow us on LinkedIn.